8th Oct 2021 21:39
Arix Bioscience PLC - London-based venture capital investor in biotech firms - Notes portfolio company Pyxis Oncology Inc prices its initial public offering of 10.5 million shares at a price of USD16.00 per share for gross proceeds of USD167.2 million. Says IPO resulted in an GBP6.0 million increase in the value of Arix's existing holding in Pyxis, which was valued at GBP10.8 million at June 30. Further, Mark Chin, Arix managing director, will continue to serve on Pyxis' board.
Current stock price: 141.80 pence
Year-to-date change: down 35%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L